HOME >> BIOLOGY >> NEWS
Malaria and Epstein-Barr virus linked to pediatric cancer in Africa

Endemic Burkitt lymphoma is a form of cancer that accounts for up to 74% of malignant disorders in children in equatorial Africa. Malaria and Epstein-Barr virus (EBV) are known cofactors in its development, but to date, their relative contribution has not been well understood. In a new study published online in the open-access journal PLoS Pathogens, researchers at the Karolinska Institutet in Stockholm explain how certain Plasmodium falciparum antigens directly induce Epstein-Barr virus (EBV) reactivation, increasing the risk of Burkitt lymphoma.

EBV is a ubiquitous virus that establishes a lifelong persistence following primary infection. How EBV affects its host hinges on a balance between viral latency, viral replication, and host immune responses. Generally harmless in almost every host and rarely a cause of disease, reactivation of EBV has been causally associated with various cancers. Acute malaria infection is known to increase the level of circulating EBV, but the precise mechanisms through which this virus reactivation occurs had been previously unknown.

Now, Arnaud Chene and colleagues have identified CIDRla as the first microbial protein able to spur a latently EBV-infected cell into active production. Their results suggest that P. falciparum-derived proteins can lead to a direct reactivation of EBV during acute malaria infection, increasing the risk of Burkitt lymphoma development for children living in malaria-endemic areas.


'"/>

Contact: Johanna Dehlinger
press@plos.org
415-624-1202
Public Library of Science
7-Jun-2007


Page: 1

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria in pregnancy: What can the social sciences contribute?
4. Malaria: The right vaccine in the right place?
5. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
6. 20 Years of Malaria Research: Outcomes and Perspectives
7. Malaria poses additional risks for first-time mothers
8. Malaria drug may treat metabolic syndromes many symptoms
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... , ... Leaders of Quorum Review IRB and Kinetiq , ... this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo ... "We are excited to present subject matter expertise on topics that impact the global ...
(Date:4/21/2017)... Austin, TX (PRWEB) , ... April 21, 2017 , ... ... more than a year, Formaspace is pleased to introduce it to top lab design ... Carolina. Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey ...
(Date:4/21/2017)... ... 2017 , ... Frederick Innovative Technology Center, Inc. (FITCI), a ... technology start-ups, is hosting “Celebration Friday” (a festive gathering highlighting client success stories) ... and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court location, off English ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
Breaking Biology Technology:
Cached News: